Lantheus Holdings, Inc. (LNTH)
After hours:
| Previous Close | 65.21 |
| Open | 63.02 |
| Bid | 65.19 x 100 |
| Ask | 65.26 x 100 |
| Day's Range | 63.76 - 65.27 |
| 52 Week Range | 50.20 - 100.85 |
| Volume | |
| Avg. Volume | 860,151 |
| Market Cap | 4.47B |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | 14.02 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024, to discuss its financial and operating results for the first quarter of 2024. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minu
- GlobeNewswire
Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the Leerink Partners Global Biopharma Conference 2024 at 9:20 a.m. ET on Tuesday, March 12. To access a live webcast of the presentation, please visit the Investors section of the Comp
- GlobeNewswire
Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients
DEFINITY is the #1 utilized ultrasound enhancing agent in the U.S. for patients with suboptimal echocardiogramsBEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow® disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for DEFINI
